乳癌细胞系的DARC表达的调节机制以及患者Duffy血型与病理关系的研究
|
摘要
[目的]DARC是Duffy抗原/趋化因子受体(Duffy antigen/Receptor 0fChemokine)的简称。Duffy抗原和DARC是有同样结构和功能的蛋白质分子,它们的区别仅仅在于Duffy抗原位于红细胞上,而DARC位于乳腺癌细胞等其它非红细胞上。Duffy抗原决定了Duffy血型。DARC是乳腺癌的负性调控因子,它和乳腺癌关系密切;另外,已知炎症性疾病时DARC上调。因此,我们提出TNF-α等致炎性细胞因子调节乳腺癌细胞DARC表达的假设并加以验证。在患者Duffy血型与临床病理关系的研究方面,目的是验证Duffy血型(Duffy Blood Group,DBG)的表型是否与乳腺癌的发生和恶性程度有关。相关的研究背景包括:流行病学的研究表明,不同民族有不同的DBG表型分布,同时,不同民族在乳腺癌的发病率和死亡率方面也有所不同。【方法】选择常见的四种致炎性细胞因子TNF-α、IL-1β、IFN-γ和IL-8,以乳腺癌MDA-MB-231细胞系为研究对象,应用Real-Time PCR和Western-Blot方法,检测这些致炎性细胞因子能否调节MDA-MB-231的DARC表达。在初步验证TNF-α可以上调DARC的表达κ之后,进一步检测TNF-α抗体和NF-κB(nuclear factor-kappaB,核转录因子κB)抑制剂AEA(anadmide,NF-κB阻滞剂)对于DARC表达的影响。本实验还采用ELISA定量内源性TNF-α的浓度,确定内源性TNF-α对DARC表达的影响。最后应用Transwell观察TNF-α上调乳腺癌细胞系DARC表达后,细胞对于趋化因子CXCL8、CCL2的清除能力、细胞的趋化运动、侵袭能力是否改变以确定DARC的这种上调是否具有功能。在Duffy血型与临床病理关系的研究方面,我们采用了非直接抗人球蛋白法检验了复旦大学附属上海肿瘤医院乳腺科的连续253例女性病人的DBG表型,根据凝血情况分为Fya+Fyb-、Fya-Fvb+、Fya+Fyb+和Fya-Fyb-四种表型。在此基础上分析DBG表型与病理之间的关系。【结果】0.5～1ng/ml的TNF-α上调mDARC4～8倍。4～8ng/ml的IL-1β可以上调DARC 7倍左右。IFN-γ和IL-8对DARC表达的影响较小。应用TNF-α抗体后,TNF-α上调DARC的作用减弱。DARC的上调或下调时,其mRNA和蛋白的变化是同步的。AEA25μM作用后,TNF-α上调DARC的作用降低。内源性TNF-α对DARC表达没有显著影响。TNF-α上调乳腺癌细胞系的DARC表达后,细胞对于趋化因子CXCL8、CCL2的清除能力提高了,同时提高了细胞对于CXCL8、CCL2的趋化运动,并且降低了细胞的侵袭运动能力。在Duffy血型与病理关系的研究方面,我们发现有乳腺疾病或有乳腺癌的汉族女性患者和普通汉族人群在DBG表型分布方面的差异无显著性。在乳腺癌的发病方面,Fya-Fyb-和Fya-Fyb+有更高的乳腺癌的发病倾向性,但没有统计学的差异;Fya-表型的患者群和Fya+表型的患者群相比有更高的恶性率,但没有统计学的差异(两者分别为57.14%和39.02%,P=0.28)。各表型之间在ER、PR、Her-2、P53、PCNA、PS2、nm23和P450状态方面没有差异;在乳腺癌的病理分级方面也没有统计学差异。表型Fya-的患者比Fya+的患者有更高的腋淋巴结转移率(分别是100%和39.13%,P＜0.05,FisHer精确检验)。[结论]TYF-α和IL-1β对于DARC的表达起重要作用。TNF-α对DARC的调节可能通过NF-κB起作用。乳腺癌细胞系MDA-MB-231自身分泌的TNF-α对于DARC的调节功能并不重要。在Dufry血型与病理关系的研究方面,本研究表明,对于乳腺癌患者的腋淋巴结转移,Dufry血型表型体系中的Fya抗原比Fyb抗原更加重要。Fya-表型对于发现腋淋巴结转移的倾向的乳腺癌患者有帮助
Purpose:DARC is the abbreviation of Duffy antigen/Receptor of Chemokine, which is a negative regulator to breast cancer.Duffy Blood Group(DBG) is determined by Duffy antigen.Duffy antigen and DARC is the identical protein which share the same structure and function.The only difference between Duffy antigen and DARC is the former is located in the membrane of red bolld cell and the latter is located in the membrane of breast cancer cells and other cells such as endothelial cells.Our lab previous study suggested that DARC correlated to breast cancer malignancy.Besides,DARC is up-regulated in several inflammatory diseases. In this study we test the hypothesis that whether pro-inflammatory cytokines can up-regulate DARC in breast cancer cell lines based on such background.Another hypothesis we test is that clinical patients' DBG phenotypes affect on breast cancer occurrence and correlate to malignancy based on the epidemiological facts that different races has definitely different DBG phenotypes distribution and to them, there is a various breast cancer mobidity and mortality.Methods:Real-Time PCR and Western-Blot analysis was used to test four pro-inflammatory cytokines TNF-α, IL-1β,IFN-γand IL-8 effects on MDA-MB-231 cell lines DARC mRNA and protein expression.After we founded that TNF-αincrease DARC expression at both mRNA and protein level,we tested TNF-αantibody and NF-κB inhibitor AEA(Anadmide) effects on DARC by Real-Time PCR and Western-Blot analysis.Concentration of endogenous TNF-αwas determined by Enzyme Linked Immunosorbent Assay (ELISA).Finally,ELISA measured the concentration of CXCL8(CXC chemokine ligand 8,interleukin-8,IL-8),CCL2(CC chemokine ligand 2,two major DARC ligands,in conditioned media were done to determine DARC chemotactic clearance, and Transwell migration assays towards CCL2 as well as in vitro invasion assay were done to determine whether the TNF-α-induced increase in DARC expression was functional.In the study about correlation between DBG and pathological diagnosie,we investigated DBG phenotypes of 253 cases consecutive hospitalized female patients suffering breast disease in Shanghai Cancer Hospital and analysized its relationship with clinical pathological diagnosis.DBG phenotypes were examined by indirect antiglobulin-test with anti-Fya and anti-Fyb reagents and were classified into Fya+Fyb-,Fya-Fyb+,Fya+Fyb+,Fya-Fyb- according agglutination.Results: TNF-α(0.5～1ng/ml) and IL-1β(4～8ng/ml) obviously increased DARC expression by 4 to 8 folds and 7 folds respectly.TNF-αantibody and NF-κB inhibitor AEA(25μM) attenuated TNF-αup-regulation.IFN-γand IL-8 effects on DARC expression were weak.No correlation between concentration of endogenous TNF-αand DARC expression.DARC expression level in mRNA and protein was paralleled.TNF-αinduced DARC expression enhanced clearance of chemokines,moreover,mobility of MDA-MD-231 cell line to CCL2 was increased and invasion capacity of MDA-MD-231 cell line was decreased.DARC increased by TNF-αwas functional. In the study about correlation between DBG and pathological diagnosie,we found neither DBG phenotypes distribution difference existed in breast disease patients nor DBG phenotypes distribution difference existed in breast cancer patients compared to general Chinese Han population.To breast cancer occurring possibility,Fya-Fyb-and Fya-Fyb+ demonstrated more susceptibility to breast cancer than Fya+Fyb- and Fya+Fyb+,but no statistical significant difference.Fya- group(57.14%) had more malignant incidence than that of Fya+ group(39.02%),but no statistical significance (P=0.28).Neither significant difference had been observed in ER,PR,Her-2 status and P53,PCNA,PS2,nm23,P450 status between every DBG phenotypes,nor statistical difference was found to tumor grades in various DBG phenotypes.More patients were involved in auxiliary lymph nodes metastasis in Fya- than that of Fya+ group and reached a statistical significance(100%and 39.13%respectively,P＜0.05, Fisher exact test).Conclusion:Both TNF-αand IL-1βare two important regulators to breast cancer cell lines MDA-MB-231 DARC expression and the function may via NF-κB pathway.Endogenous TNF-αwas not an important redulator to DARC expression.Fya antigen weights more than Fyb antigen in breast cancer lymphnodes metastasis.Fya negative maybe a clinically useful factor to identify the potential axillary lymph nodes metastasis in breast cancer patients.
Purpose:DARC is the abbreviation of Duffy antigen/Receptor of Chemokine, which is a negative regulator to breast cancer.Duffy Blood Group(DBG) is determined by Duffy antigen.Duffy antigen and DARC is the identical protein which share the same structure and function.The only difference between Duffy antigen and DARC is the former is located in the membrane of red bolld cell and the latter is located in the membrane of breast cancer cells and other cells such as endothelial cells.Our lab previous study suggested that DARC correlated to breast cancer malignancy.Besides,DARC is up-regulated in several inflammatory diseases. In this study we test the hypothesis that whether pro-inflammatory cytokines can up-regulate DARC in breast cancer cell lines based on such background.Another hypothesis we test is that clinical patients' DBG phenotypes affect on breast cancer occurrence and correlate to malignancy based on the epidemiological facts that different races has definitely different DBG phenotypes distribution and to them, there is a various breast cancer mobidity and mortality.Methods:Real-Time PCR and Western-Blot analysis was used to test four pro-inflammatory cytokines TNF-α, IL-1β,IFN-γand IL-8 effects on MDA-MB-231 cell lines DARC mRNA and protein expression.After we founded that TNF-αincrease DARC expression at both mRNA and protein level,we tested TNF-αantibody and NF-κB inhibitor AEA(Anadmide) effects on DARC by Real-Time PCR and Western-Blot analysis.Concentration of endogenous TNF-αwas determined by Enzyme Linked Immunosorbent Assay (ELISA).Finally,ELISA measured the concentration of CXCL8(CXC chemokine ligand 8,interleukin-8,IL-8),CCL2(CC chemokine ligand 2,two major DARC ligands,in conditioned media were done to determine DARC chemotactic clearance, and Transwell migration assays towards CCL2 as well as in vitro invasion assay were done to determine whether the TNF-α-induced increase in DARC expression was functional.In the study about correlation between DBG and pathological diagnosie,we investigated DBG phenotypes of 253 cases consecutive hospitalized female patients suffering breast disease in Shanghai Cancer Hospital and analysized its relationship with clinical pathological diagnosis.DBG phenotypes were examined by indirect antiglobulin-test with anti-Fya and anti-Fyb reagents and were classified into Fya+Fyb-,Fya-Fyb+,Fya+Fyb+,Fya-Fyb- according agglutination.Results: TNF-α(0.5～1ng/ml) and IL-1β(4～8ng/ml) obviously increased DARC expression by 4 to 8 folds and 7 folds respectly.TNF-αantibody and NF-κB inhibitor AEA(25μM) attenuated TNF-αup-regulation.IFN-γand IL-8 effects on DARC expression were weak.No correlation between concentration of endogenous TNF-αand DARC expression.DARC expression level in mRNA and protein was paralleled.TNF-αinduced DARC expression enhanced clearance of chemokines,moreover,mobility of MDA-MD-231 cell line to CCL2 was increased and invasion capacity of MDA-MD-231 cell line was decreased.DARC increased by TNF-αwas functional. In the study about correlation between DBG and pathological diagnosie,we found neither DBG phenotypes distribution difference existed in breast disease patients nor DBG phenotypes distribution difference existed in breast cancer patients compared to general Chinese Han population.To breast cancer occurring possibility,Fya-Fyb-and Fya-Fyb+ demonstrated more susceptibility to breast cancer than Fya+Fyb- and Fya+Fyb+,but no statistical significant difference.Fya- group(57.14%) had more malignant incidence than that of Fya+ group(39.02%),but no statistical significance (P=0.28).Neither significant difference had been observed in ER,PR,Her-2 status and P53,PCNA,PS2,nm23,P450 status between every DBG phenotypes,nor statistical difference was found to tumor grades in various DBG phenotypes.More patients were involved in auxiliary lymph nodes metastasis in Fya- than that of Fya+ group and reached a statistical significance(100%and 39.13%respectively,P＜0.05, Fisher exact test).Conclusion:Both TNF-αand IL-1βare two important regulators to breast cancer cell lines MDA-MB-231 DARC expression and the function may via NF-κB pathway.Endogenous TNF-αwas not an important redulator to DARC expression.Fya antigen weights more than Fyb antigen in breast cancer lymphnodes metastasis.Fya negative maybe a clinically useful factor to identify the potential axillary lymph nodes metastasis in breast cancer patients.
引文
1.Neote K,Mak JY,Kolakowski LF Jr,Schall TJ.Functional and biochemical analysis of the cloned Duffy antigen,identity with the red blood cell chemokine receptor.[J].Blood,1994,84(1):44-52.
2.Chaudhuri A,Zbrzezna V,Polyakova J,Pogo AO,Hesselgesser J.Horuk R.Expression of the Duffy antigen in K562 cells Evidence that it is the human erythrocyte chemokine receptor.[J].J Biol Chem,1994,269(11):7835-7838.
3.Lachgar A,Jaureguiberry G,Le Buenac H,et al.Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines(DARC)[J].Biomed Pharmacother,1998,52(10):436-439.
4.Singh SK,Hora R,Belrhali H,et al.Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain[J].Nature,2006,439(9):741-744.
5.Akalin,Enver,Neylan,John F.The influence of Duffy blood group on renal allograft outcome in african Americans[J].Transplantation,2003,75(9):1496-1500.
6.Pittoni V,Vaglio S,Magrini L,et al.Polymorphism of the Duffy erythrocyte chemokine receptor in Italian patients with Behcet's disease[J].Rheumatol Int,2003,23(3):116-120.
7.Lentsch AB.The Duffy antigen/receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white?[J].FASEB J,2002,16(9):1093-1095.
8.Hora R,Belrhali H,Chitnis CE,et al.The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.Singh SK[J].Nature,2006,439(9):741-744.
9.Christina L Addison,John A Belperio.Overexpression of the Duffy antigen receptor for chemokines(DARC) by NSCLC tumor cells results in increased tumor necrosis[J].BMC Cancer.2004;4:28.
10.Wang J,Ou ZL,Hou YF,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential [J]Oncogene,2006,25(54):7201-7211.
11.Liu XH,Hadley TJ,Xu L,et al.Up-regulation of Duffy antigen receptor expression in children with renal disease[J].Kidney Int,1999,55(4):1491-1500.
12.Patterson AM,Siddall H,Chamberlain G,et al.Expression of the Duffy antigen/receptor for chemokines(DARC) by the inflamed synovial endothelium.[J].J Pathol,2002,197(1):108-116.
13.Segerer S,Regele H,MacK M,et al.The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis[J].Kidney Int,2000,58(4):1546-1556.
14.Hagemann T,Szlosarek PW,Balkwill FR,et al.The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Kulbe H[J].Cancer Res,2005,65(22):10355-10362.
15.杜若甫.中国人群体遗传学[M],北京:科学出版社,2004年:121-126.
1.Sancho R,Calzado MA,Di Marzo V,et al.Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway [J].Mol Pharmacol,2003,63(2):429-438.
2.Wang J,Ou ZL,Hou YF,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential[J].Oncogene,2006,25(54):7201-7211.
3.J萨姆布鲁克,D.W.拉塞尔.分子克隆[M],北京:科学出版社,2006年:1713-1726.
4.Hagemann T,Szlosarek PW,Balkwill FR,et al.The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Kulbe H[J].Cancer Res,2005,65(22):10355-10362.
5.Awane M,Andres PG,Li DJ,et al.NF-kappa B-inducing kinase is a common mediator of IL-17-,TNF-alpha-,and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells[J].J Immunol,1999,162(9):5337-5344.
6.Oh JW,Drabik K,Kutsch O,et al.chemokine receptor 4 expression and function in human astroglioma cells[J].J Immunol,2001,166(4):2695-2704.
7.Lane BR,Markovitz DM,Woodford NL,et al.TNF-alpha inhibits HIV-1replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5(CCRS)expression[J].J Immunol,1999,163(7):3653-3661.
8.Kohsuke Asagoe,Kokichi Yamamoto,Atsushi Takahashi,et al.Down-Regulation of CXCR2 Expression on Human Polymorphonuclear Leukocytes by TNF-α[J].J.Immunol,1998,160:4518.
9.Auphan N,DiDonato JA,Rosette C,Helmberg A,Karin M.Immunosuppression by glucocorticoids:inhibition of NF-kappa B activity through induction of I kappa B Synthesis[J].Science(Biology),1995,270(5234):286-290.
10.Haskill S,Beg AA,Tompkins SM,et al.Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity[J].Cell,1991,65(7):1281-1289.
11.Traenckner EB,Pahl HL,Henkel T,Schmidt KN,Wilk S,Baeuerle PA.Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli[J].EMBO J,1995,14(12):2876-2883.
12.Liu XH,Hadley TJ,Xu L,et al.Up regulation of Duffy antigen receptor expression in children with renal diseases[J].Kindey Int,1999,55:1491-1500.
13.Lautenberger JA,Stephens JC,O'Brien S J,et al.Significant admixture linkage disequilibrium across 30cM around the FY locus in African Americans[J].Am J Hum Genet,2000,66(3):969-978.
14.Singh SK,Hora R,Belrhali H,et al.Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain[J].Nature,2006,439(7077):741-744.
15.Lachgar A,Jaureguiberry G,Le Buenac H,et al.Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines(DARC)[J].Biomed Pharmacother,1998,52(10):436-439.
16.Dawson TC,Lentsch AB,Wang Z,et al.Exaggerated response to endotoxin mice lacking the Duffy antigen receptor for chemokines(DARC)[J].Blood,2000,96(5):1681-1684.
17.Lentsch AB.The Duffy antigen receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white[J].FASEB,2002,16(9):1093-1095.
18.高菊兴,张纪云,董庆玉.乳腺癌患者血清LEP、IGF-1和TNF-α测定的临床意义[J].检验医学,2005,20(1):28-29.
19.杨振林,刘敬波,张岩江等.乳腺癌患者血清肿瘤坏死因子白细胞介素6和白细胞介素2水平的变化及其临床意义[J].中华普通外科杂志,2001,16(11):678-679.
20.Vahdat LT,Cohen DJ,Zipin D,et al.Randomized trial of low-dose interleukin-2vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer[J].Bone Marrow Transplant,2007,40(3):267-272.
21.刘刚.乳腺癌患者外周血中趋化因子的检测及临床意义[J].中国癌症杂志,2003,13(4).
22.Addison CL,Arenberg DA,Morris SB,et al.The CXC chemokine,monokine induced by interferon-gamma,inhibits non-small cell lung carcinoma tumor growth and metastasis[J].Hum Gene Ther,2000,11:247-261.
23.Salcedo R,Resau JH,Halverson D,et al.Differential expression and responsiveness of chemokine receptors(CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells[J].FASEB J,2000,14:2055-2064
24.Bendre MS,Gaddy-Kurten D,Mon-Foote T,et al.Expression of interleukin 8and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo[J].Cancer Res,2002,62(19):5571-5579.
25.De Larco JE,Wuertz BR,Rosner KA,et al.A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells[J].Am J Pathol,2001,158(2):639-646.
26.Salcedo R,Ponce ML,Young HA,et al.Human endothelial cells express CCR2and respond to MCP-I:direct role of MCP-1 in angiogenesis and tumor progression[J].Blood,2000,96(1):34-40.
27.Masson S,Scotte M,Francois A.Changes in growth factor and cytokine mRNA levels after hepatectomy in rat with CC14-induced cirrhosis[J].Am J Physiol,1999,277:G838-G846.
28.Pogo AO,Chaudhuri A.The Duffy protein:a malarial and chemokine receptor[J].Semin Hematol,2000,37(2):122-129.
29.Akalin E,Neylan JF.The influence of Duffy blood group on renal allograft outcome in African Americans[J].Transplantation,2003,75(9):1496-1500.
30.Neote K,Mak JY,Kolakowski LF Jr,Schall TJ.Functional and biochemical analysis of the cloned Duffy antigen:identity with the red blood cell chemokine receptor[J].Blood,1994,84(1):44-52.
31.Chaudhuri A,Zbrzezna V,Polyakova J,Pogo AO,Hesselgesser J,Horuk R.Expression of the Duffy antigen in K562 cells.Evidence that it is the human erythrocyte chemokine receptor[J].J Biol Chem,1994,269(11):7835-7838.
32.Pittoni,V.Vaglio,S.Magrini,L.et al.Polymorphism of the Duffy erythrocyte chemokine receptor in Italian patients with Behcet's disease[J].Rheumatol Int,2003,23(3):116-120.Epub 2003 Jan 18.
33.Ogawa Y,Moriya T,Kato Y,Oguma M,Ikeda K,Takashima T,Nakata B,Ishikawa T,Hirakawa K.Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer:analysis for a cut-off point as the predictor for endocrine therapy[J].Breast Cancer,2004,11(3):267-275.
34.Taylor SL,Platt-Higgins A,Rudland PS,Winstanley JH,Barraclough R.Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens[J].Int J Cancer,1998,76(4):459-463.
35.何清波,苏秉华,钱亢.医学统计学及其软件包[M],上海上海科学技术文献出版社,2002年:183-219.
36.Peng CT,Tsai CH,Lee HI-I,et al.Molecular analysis of Duff-y,Yt and Colton blood groups in Taiwanese,Filipinos and Thais[J].Kaohsiung J Med Sci,2000,16(2):63-67.
37.杜若甫.中国人群体遗传学[M],北京:科学出版社,2004年:121—126.
38.Liu XH,Hadley TJ,Xu L,et al.Up regulation of Duffy antigen receptor expression in children with renal diseases[J].Kindey Int 1999,55:1491- 1500.
39.Terence JH,Stephen CP.From Malaria to Chemokine Receptor:The Emerging Physiologic Role of the Duffy Blood Group Antigen[J].Blood,1997,89:3077-3091.
40.Neote K,Mak JY,Kolakowski LF,et al.Functional and biochemical analysis of the cloned Duffy antigen:identity with the red blood cell chemokine receptor[J].Blood,1994,84(1):44-52.
41.Comerford I,Nibbs RJ.Post-translational control of chemokines:a role for decoy receptors?[J].Immunol Lett,2005,96(2):163-174.
42.Lentsch AB.The Duffy antigen receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white[J].FASEB,2002,16(9):1093-1095.
43.Nibbs RJ,Wylie SM,Yang J,et al.Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6[J].J Biol Chem,1997,272(51):32078-32083.
44.Blackburn PE.Purification and biochemical characterization of the D6chemokine receptor[J].Biochem J,2004,379(Pt 2):263-272.
45.Woolley IJ,Hotmire KA,Sramkoski RM,et al.Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype[J].Transfusion,2000,40(8):949-953.
46.Horuk R,Wang ZX,Peiper SC,et al.Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line[J].J Biol Chem,1994,269(26):17730-17733.
47.Staller P,Sulitkova J,Lisztwan J,et al.Chemokine receptor CXCR4 down regulated by yon Hippel Lindau turnout suppressor pVHL[J].Nature,2003,425(6955):307-311.
48.Bertolini F,Dell'Agnola C,Mancuso P,et al.CXCR4 neutralization,a novel therapeutic approach for non-Hodgkin's lymphoma[J].Cancer Res,2002,62(11):3106-3112.
49.Addison CL,Arenberg DA,Morris SB,et al.The CXC chemokine,monokine induced by interferon-gamma,inhibits non- small cell lung carcinoma tumor growth and metastasis[J].Hum Gene Ther,2000,11:247-261.
50.Salcedo R,Resau JH,Halverson D,et al.Differential expression and responsiveness of chemokine receptors(CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells[J].FASEB J,2000,14:2055-2064
51.Bendre MS,Gaddy-Kurten D,Mon-Foote T,et al.Expression of interleukin 8and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo[J].Cancer Res,2002,62(19):5571-5579.
52.De Larco JE,Wuertz BR,Rosner KA,et al.A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells[J].Am J Pathol,2001,158(2):639-646.
53.Salcedo R,Ponce ML,Young HA,et al.Human endothelial cells express CCR2and respond to MCP-1:direct role of MCP-1 in angiogenesis and tumor progression[J].Blood,2000,96(1):34-40.
54.Margit CS,Kenneth SS,Albert Z,et al.Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor[J].J Biol Chem,1995,270:25348-25351.
1.Lee YK,So IS,Lee SC,Lee JH,Lee CW,Kim WM,Park MK,Lee ST,Park DY,Shin DY,Park CU,Kim YS.Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer[J].J Gene Med,2005,7(2):145-157.
2.Waterhouse DN,Dragowska WH,Gelmon KA,Mayer LD,Bally MB.Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6human breast cancer model[J].Cancer Biol THer,2004,3(2):197-204.
3.Liu RB,Rabkin SD.Oncolytic Herpes simplex virus vectors for the treatment of human breast cancer[J].Chin Med J(Engl),2005,118(4):307-312.
4.Akla B,Monteil J,Paraf F,Sturtz F,Rigaud M.A new orthotopic model of human breast cancer in immunocompetent rats[J].Anticancer Res,2003,23(5A):3761-3766.
5.Jones LW,Eves ND,Courneya KS,Chiu BK,Baracos VE,Hanson J,Johnson L,Mackey JR.Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts[J].Clin Cancer Res,2005,11(18):6695-6698.
6.Burch S,Bisland SK,Bogaards A,Yee AJ,Whyne CM,Finkelstein JA,Wilson BC.Photodynamic tHerapy for the treatment of vertebral metastases in a rat model of human breast carcinoma[J].J Orthop Res,2005,23(5):995-1003.
7.SutHerland TE,Schuliga M,Harris T,Eckhardt BL,Anderson RL,Quan L,Stewart AG.2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer[J].Clin Cancer Res,2005,11(5):1722-1732.
8.Welm AL, Kim S, Welm BE, Bishop JM.MET and MYC cooperate in mammary tumorigenesis[J].Proc Natl Acad Sci U S A, 2005,102(12):4324-4329.
9.Grossi PM, Ochiai H, ArcHer GE. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer[J]. Clin Cancer Res, 2003, 9(15):5514-5520.
10.Espana L, Fernandez Y, Rubio N.Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis[J].Breast Cancer Res Treat, 2004,87(1):33-44.
11. Nozaki S, Maeda M, Tsuda H, Sledge GW Jr.Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent[J]. irsogladine Breast Cancer Res Treat, 2004, 83(3): 195-199.
12. Hu WX, Zeng ZJ, Luo SQ, Chen Q. Suicide gene tHerapy of human breast cancer in SCID mice model by the regulation of Tet-On[J]. Chin Med J (Engl), 2004, 117(3): 434-439.
13. Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models[J].Breast Cancer Res Treat, 2004, 87(1): 97-107.
14. Mehta RR, Graves JM, Hart GD, Shilkaitas A, DasGupta TK. Growth and metastasis of human breast carcinomas with matrigel in athymic mice[J]. Breast Cancer Res Treat, 1993, 25:65-71.
15. Ewens A, Mihich E, Ehrke MJ.Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma[J]. Anticancer Res, 2005, 25 (6B): 3905-3915.
16. Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis[J]. Clin Exp Metastasis, 2005, 22(1): 1-9.
17. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF.Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model[J]. Cancer Res, 2005, 65(8):3396-3403.
18.Bandyopadhyay A, Elkahloun A, Baysa SJ, Wang L, Sun LZ. Development and gene expression profiling of a metastatic variant of the human breast cancer MDA-MB-435 cells [J]. Cancer Biol THer, 2005,4(2):168-174.
19. Nukatsuka M, Fujioka A, Nakagawa F.Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model[J]. Int J Oncol, 2004, 25(6): 1531-1536.
20.Li X, Wang J, An Z, Yang M, Baranov E, Jiang P, Sun F, Moossa AR, Hoffman RM.Optically imageable metastatic model of human breast cancer[J]. Clin Exp Metastasis, 2002, 19(4):347-350.
21. Mendes O, Kim HT, Stoica G.Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model[J]. Clin Exp Metastasis, 2005, 22(3): 237-246.
22. Myoui A, Nishimura R, Williams PJ. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis [J]. Cancer Res, 2003, 63(16):5028-5033.
23. A Sasaki, BF Boyce, B Story, KR Wright, M Chapman, R Boyce, GR Mundy and T Yoneda Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice[J].Cancer Research, 1995,55(16): 3551-3557.
24.Bing Yi, Paul J. Williams, Marie Niewolna, Yakun Wang and Toshiyuki Yoneda Tumor-derived Platelet-derived Growth Factor-BB Plays a Critical Role in Osteosclerotic Bone Metastasis in an Animal Model of Human Breast Cancer [J].Cancer Research2002, 62(1): 917-923.
25. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M.A mouse model of human breast cancer metastasis to human bone [J]. Cancer Res, 2005 ,65(14):6130-6138.
26.Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein[J]. Int J Cancer, 2005, 115(2): 177-186.
27. Neudert M, FiscHer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth[J]. Int J Cancer, 2003, 107(3): 468-477.
28. Waterhouse DN, Gelmon KA, Masin D, Bally MB.Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model[J]. J Exp THer Oncol, 2003, 3(5):261-271.
29. Brodie AH, Jelovac D, Long B.The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens[J]. J Steroid Biochem Mol Biol, 2003, 86(3-5):283-288.
30.Danijela Jelovac, Luciana Macedo, Olga G. Goloubeva, Venkatesh Handratta and Angela M.H. Brodie Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model[J].Cancer Res, 2005, 65(12): 5439-5444.
31. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development [J]. Cancer Res, 2005, 65(18):8166-8173.
32. Lee JL, Chang CJ, Wu SY. Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands[J]. Breast Cancer Res Treat, 2004, 84(2): 139-149.
33. Perez-Alenza MD, Jimenez A, Nieto AI, Pena L. First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases [J]. Breast Cancer Res, 2004, 6(4):R300-307.
34.Raffaella De Maria~1, Martina Olivero, Selina Iussich, Munekazu Nakaichi, Tomoaki Murata, Bartolomeo Biolatti and Maria Flavia Di Renzo. Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer Cancer Research February 1, 2005,65, 907-912,
35. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD.CXCR4 regulates growth of both primary and metastatic breast cancer[J]. Cancer Res, 2004, 64(23):8604-8612.
36.Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, MukHerjee P.Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer[J]. Mol Cancer Res, 2004, 2(11): 632-642.
37.Hu Y,Sun H,Drake J,Kittrell F.From mice to humans:identification of commonly deregulated genes in mammary cancer via comparative SAGE studies [J].Cancer Res,2004,64(21):7748-7755.
2.Chaudhuri A,Zbrzezna V,Polyakova J,Pogo AO,Hesselgesser J.Horuk R.Expression of the Duffy antigen in K562 cells Evidence that it is the human erythrocyte chemokine receptor.[J].J Biol Chem,1994,269(11):7835-7838.
3.Lachgar A,Jaureguiberry G,Le Buenac H,et al.Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines(DARC)[J].Biomed Pharmacother,1998,52(10):436-439.
4.Singh SK,Hora R,Belrhali H,et al.Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain[J].Nature,2006,439(9):741-744.
5.Akalin,Enver,Neylan,John F.The influence of Duffy blood group on renal allograft outcome in african Americans[J].Transplantation,2003,75(9):1496-1500.
6.Pittoni V,Vaglio S,Magrini L,et al.Polymorphism of the Duffy erythrocyte chemokine receptor in Italian patients with Behcet's disease[J].Rheumatol Int,2003,23(3):116-120.
7.Lentsch AB.The Duffy antigen/receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white?[J].FASEB J,2002,16(9):1093-1095.
8.Hora R,Belrhali H,Chitnis CE,et al.The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.Singh SK[J].Nature,2006,439(9):741-744.
9.Christina L Addison,John A Belperio.Overexpression of the Duffy antigen receptor for chemokines(DARC) by NSCLC tumor cells results in increased tumor necrosis[J].BMC Cancer.2004;4:28.
10.Wang J,Ou ZL,Hou YF,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential [J]Oncogene,2006,25(54):7201-7211.
11.Liu XH,Hadley TJ,Xu L,et al.Up-regulation of Duffy antigen receptor expression in children with renal disease[J].Kidney Int,1999,55(4):1491-1500.
12.Patterson AM,Siddall H,Chamberlain G,et al.Expression of the Duffy antigen/receptor for chemokines(DARC) by the inflamed synovial endothelium.[J].J Pathol,2002,197(1):108-116.
13.Segerer S,Regele H,MacK M,et al.The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis[J].Kidney Int,2000,58(4):1546-1556.
14.Hagemann T,Szlosarek PW,Balkwill FR,et al.The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Kulbe H[J].Cancer Res,2005,65(22):10355-10362.
15.杜若甫.中国人群体遗传学[M],北京:科学出版社,2004年:121-126.
1.Sancho R,Calzado MA,Di Marzo V,et al.Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway [J].Mol Pharmacol,2003,63(2):429-438.
2.Wang J,Ou ZL,Hou YF,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential[J].Oncogene,2006,25(54):7201-7211.
3.J萨姆布鲁克,D.W.拉塞尔.分子克隆[M],北京:科学出版社,2006年:1713-1726.
4.Hagemann T,Szlosarek PW,Balkwill FR,et al.The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Kulbe H[J].Cancer Res,2005,65(22):10355-10362.
5.Awane M,Andres PG,Li DJ,et al.NF-kappa B-inducing kinase is a common mediator of IL-17-,TNF-alpha-,and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells[J].J Immunol,1999,162(9):5337-5344.
6.Oh JW,Drabik K,Kutsch O,et al.chemokine receptor 4 expression and function in human astroglioma cells[J].J Immunol,2001,166(4):2695-2704.
7.Lane BR,Markovitz DM,Woodford NL,et al.TNF-alpha inhibits HIV-1replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5(CCRS)expression[J].J Immunol,1999,163(7):3653-3661.
8.Kohsuke Asagoe,Kokichi Yamamoto,Atsushi Takahashi,et al.Down-Regulation of CXCR2 Expression on Human Polymorphonuclear Leukocytes by TNF-α[J].J.Immunol,1998,160:4518.
9.Auphan N,DiDonato JA,Rosette C,Helmberg A,Karin M.Immunosuppression by glucocorticoids:inhibition of NF-kappa B activity through induction of I kappa B Synthesis[J].Science(Biology),1995,270(5234):286-290.
10.Haskill S,Beg AA,Tompkins SM,et al.Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity[J].Cell,1991,65(7):1281-1289.
11.Traenckner EB,Pahl HL,Henkel T,Schmidt KN,Wilk S,Baeuerle PA.Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli[J].EMBO J,1995,14(12):2876-2883.
12.Liu XH,Hadley TJ,Xu L,et al.Up regulation of Duffy antigen receptor expression in children with renal diseases[J].Kindey Int,1999,55:1491-1500.
13.Lautenberger JA,Stephens JC,O'Brien S J,et al.Significant admixture linkage disequilibrium across 30cM around the FY locus in African Americans[J].Am J Hum Genet,2000,66(3):969-978.
14.Singh SK,Hora R,Belrhali H,et al.Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain[J].Nature,2006,439(7077):741-744.
15.Lachgar A,Jaureguiberry G,Le Buenac H,et al.Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines(DARC)[J].Biomed Pharmacother,1998,52(10):436-439.
16.Dawson TC,Lentsch AB,Wang Z,et al.Exaggerated response to endotoxin mice lacking the Duffy antigen receptor for chemokines(DARC)[J].Blood,2000,96(5):1681-1684.
17.Lentsch AB.The Duffy antigen receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white[J].FASEB,2002,16(9):1093-1095.
18.高菊兴,张纪云,董庆玉.乳腺癌患者血清LEP、IGF-1和TNF-α测定的临床意义[J].检验医学,2005,20(1):28-29.
19.杨振林,刘敬波,张岩江等.乳腺癌患者血清肿瘤坏死因子白细胞介素6和白细胞介素2水平的变化及其临床意义[J].中华普通外科杂志,2001,16(11):678-679.
20.Vahdat LT,Cohen DJ,Zipin D,et al.Randomized trial of low-dose interleukin-2vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer[J].Bone Marrow Transplant,2007,40(3):267-272.
21.刘刚.乳腺癌患者外周血中趋化因子的检测及临床意义[J].中国癌症杂志,2003,13(4).
22.Addison CL,Arenberg DA,Morris SB,et al.The CXC chemokine,monokine induced by interferon-gamma,inhibits non-small cell lung carcinoma tumor growth and metastasis[J].Hum Gene Ther,2000,11:247-261.
23.Salcedo R,Resau JH,Halverson D,et al.Differential expression and responsiveness of chemokine receptors(CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells[J].FASEB J,2000,14:2055-2064
24.Bendre MS,Gaddy-Kurten D,Mon-Foote T,et al.Expression of interleukin 8and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo[J].Cancer Res,2002,62(19):5571-5579.
25.De Larco JE,Wuertz BR,Rosner KA,et al.A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells[J].Am J Pathol,2001,158(2):639-646.
26.Salcedo R,Ponce ML,Young HA,et al.Human endothelial cells express CCR2and respond to MCP-I:direct role of MCP-1 in angiogenesis and tumor progression[J].Blood,2000,96(1):34-40.
27.Masson S,Scotte M,Francois A.Changes in growth factor and cytokine mRNA levels after hepatectomy in rat with CC14-induced cirrhosis[J].Am J Physiol,1999,277:G838-G846.
28.Pogo AO,Chaudhuri A.The Duffy protein:a malarial and chemokine receptor[J].Semin Hematol,2000,37(2):122-129.
29.Akalin E,Neylan JF.The influence of Duffy blood group on renal allograft outcome in African Americans[J].Transplantation,2003,75(9):1496-1500.
30.Neote K,Mak JY,Kolakowski LF Jr,Schall TJ.Functional and biochemical analysis of the cloned Duffy antigen:identity with the red blood cell chemokine receptor[J].Blood,1994,84(1):44-52.
31.Chaudhuri A,Zbrzezna V,Polyakova J,Pogo AO,Hesselgesser J,Horuk R.Expression of the Duffy antigen in K562 cells.Evidence that it is the human erythrocyte chemokine receptor[J].J Biol Chem,1994,269(11):7835-7838.
32.Pittoni,V.Vaglio,S.Magrini,L.et al.Polymorphism of the Duffy erythrocyte chemokine receptor in Italian patients with Behcet's disease[J].Rheumatol Int,2003,23(3):116-120.Epub 2003 Jan 18.
33.Ogawa Y,Moriya T,Kato Y,Oguma M,Ikeda K,Takashima T,Nakata B,Ishikawa T,Hirakawa K.Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer:analysis for a cut-off point as the predictor for endocrine therapy[J].Breast Cancer,2004,11(3):267-275.
34.Taylor SL,Platt-Higgins A,Rudland PS,Winstanley JH,Barraclough R.Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens[J].Int J Cancer,1998,76(4):459-463.
35.何清波,苏秉华,钱亢.医学统计学及其软件包[M],上海上海科学技术文献出版社,2002年:183-219.
36.Peng CT,Tsai CH,Lee HI-I,et al.Molecular analysis of Duff-y,Yt and Colton blood groups in Taiwanese,Filipinos and Thais[J].Kaohsiung J Med Sci,2000,16(2):63-67.
37.杜若甫.中国人群体遗传学[M],北京:科学出版社,2004年:121—126.
38.Liu XH,Hadley TJ,Xu L,et al.Up regulation of Duffy antigen receptor expression in children with renal diseases[J].Kindey Int 1999,55:1491- 1500.
39.Terence JH,Stephen CP.From Malaria to Chemokine Receptor:The Emerging Physiologic Role of the Duffy Blood Group Antigen[J].Blood,1997,89:3077-3091.
40.Neote K,Mak JY,Kolakowski LF,et al.Functional and biochemical analysis of the cloned Duffy antigen:identity with the red blood cell chemokine receptor[J].Blood,1994,84(1):44-52.
41.Comerford I,Nibbs RJ.Post-translational control of chemokines:a role for decoy receptors?[J].Immunol Lett,2005,96(2):163-174.
42.Lentsch AB.The Duffy antigen receptor for chemokines(DARC) and prostate cancer.A role as clear as black and white[J].FASEB,2002,16(9):1093-1095.
43.Nibbs RJ,Wylie SM,Yang J,et al.Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6[J].J Biol Chem,1997,272(51):32078-32083.
44.Blackburn PE.Purification and biochemical characterization of the D6chemokine receptor[J].Biochem J,2004,379(Pt 2):263-272.
45.Woolley IJ,Hotmire KA,Sramkoski RM,et al.Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype[J].Transfusion,2000,40(8):949-953.
46.Horuk R,Wang ZX,Peiper SC,et al.Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line[J].J Biol Chem,1994,269(26):17730-17733.
47.Staller P,Sulitkova J,Lisztwan J,et al.Chemokine receptor CXCR4 down regulated by yon Hippel Lindau turnout suppressor pVHL[J].Nature,2003,425(6955):307-311.
48.Bertolini F,Dell'Agnola C,Mancuso P,et al.CXCR4 neutralization,a novel therapeutic approach for non-Hodgkin's lymphoma[J].Cancer Res,2002,62(11):3106-3112.
49.Addison CL,Arenberg DA,Morris SB,et al.The CXC chemokine,monokine induced by interferon-gamma,inhibits non- small cell lung carcinoma tumor growth and metastasis[J].Hum Gene Ther,2000,11:247-261.
50.Salcedo R,Resau JH,Halverson D,et al.Differential expression and responsiveness of chemokine receptors(CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells[J].FASEB J,2000,14:2055-2064
51.Bendre MS,Gaddy-Kurten D,Mon-Foote T,et al.Expression of interleukin 8and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo[J].Cancer Res,2002,62(19):5571-5579.
52.De Larco JE,Wuertz BR,Rosner KA,et al.A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells[J].Am J Pathol,2001,158(2):639-646.
53.Salcedo R,Ponce ML,Young HA,et al.Human endothelial cells express CCR2and respond to MCP-1:direct role of MCP-1 in angiogenesis and tumor progression[J].Blood,2000,96(1):34-40.
54.Margit CS,Kenneth SS,Albert Z,et al.Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor[J].J Biol Chem,1995,270:25348-25351.
1.Lee YK,So IS,Lee SC,Lee JH,Lee CW,Kim WM,Park MK,Lee ST,Park DY,Shin DY,Park CU,Kim YS.Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer[J].J Gene Med,2005,7(2):145-157.
2.Waterhouse DN,Dragowska WH,Gelmon KA,Mayer LD,Bally MB.Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6human breast cancer model[J].Cancer Biol THer,2004,3(2):197-204.
3.Liu RB,Rabkin SD.Oncolytic Herpes simplex virus vectors for the treatment of human breast cancer[J].Chin Med J(Engl),2005,118(4):307-312.
4.Akla B,Monteil J,Paraf F,Sturtz F,Rigaud M.A new orthotopic model of human breast cancer in immunocompetent rats[J].Anticancer Res,2003,23(5A):3761-3766.
5.Jones LW,Eves ND,Courneya KS,Chiu BK,Baracos VE,Hanson J,Johnson L,Mackey JR.Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts[J].Clin Cancer Res,2005,11(18):6695-6698.
6.Burch S,Bisland SK,Bogaards A,Yee AJ,Whyne CM,Finkelstein JA,Wilson BC.Photodynamic tHerapy for the treatment of vertebral metastases in a rat model of human breast carcinoma[J].J Orthop Res,2005,23(5):995-1003.
7.SutHerland TE,Schuliga M,Harris T,Eckhardt BL,Anderson RL,Quan L,Stewart AG.2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer[J].Clin Cancer Res,2005,11(5):1722-1732.
8.Welm AL, Kim S, Welm BE, Bishop JM.MET and MYC cooperate in mammary tumorigenesis[J].Proc Natl Acad Sci U S A, 2005,102(12):4324-4329.
9.Grossi PM, Ochiai H, ArcHer GE. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer[J]. Clin Cancer Res, 2003, 9(15):5514-5520.
10.Espana L, Fernandez Y, Rubio N.Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis[J].Breast Cancer Res Treat, 2004,87(1):33-44.
11. Nozaki S, Maeda M, Tsuda H, Sledge GW Jr.Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent[J]. irsogladine Breast Cancer Res Treat, 2004, 83(3): 195-199.
12. Hu WX, Zeng ZJ, Luo SQ, Chen Q. Suicide gene tHerapy of human breast cancer in SCID mice model by the regulation of Tet-On[J]. Chin Med J (Engl), 2004, 117(3): 434-439.
13. Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models[J].Breast Cancer Res Treat, 2004, 87(1): 97-107.
14. Mehta RR, Graves JM, Hart GD, Shilkaitas A, DasGupta TK. Growth and metastasis of human breast carcinomas with matrigel in athymic mice[J]. Breast Cancer Res Treat, 1993, 25:65-71.
15. Ewens A, Mihich E, Ehrke MJ.Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma[J]. Anticancer Res, 2005, 25 (6B): 3905-3915.
16. Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis[J]. Clin Exp Metastasis, 2005, 22(1): 1-9.
17. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF.Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model[J]. Cancer Res, 2005, 65(8):3396-3403.
18.Bandyopadhyay A, Elkahloun A, Baysa SJ, Wang L, Sun LZ. Development and gene expression profiling of a metastatic variant of the human breast cancer MDA-MB-435 cells [J]. Cancer Biol THer, 2005,4(2):168-174.
19. Nukatsuka M, Fujioka A, Nakagawa F.Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model[J]. Int J Oncol, 2004, 25(6): 1531-1536.
20.Li X, Wang J, An Z, Yang M, Baranov E, Jiang P, Sun F, Moossa AR, Hoffman RM.Optically imageable metastatic model of human breast cancer[J]. Clin Exp Metastasis, 2002, 19(4):347-350.
21. Mendes O, Kim HT, Stoica G.Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model[J]. Clin Exp Metastasis, 2005, 22(3): 237-246.
22. Myoui A, Nishimura R, Williams PJ. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis [J]. Cancer Res, 2003, 63(16):5028-5033.
23. A Sasaki, BF Boyce, B Story, KR Wright, M Chapman, R Boyce, GR Mundy and T Yoneda Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice[J].Cancer Research, 1995,55(16): 3551-3557.
24.Bing Yi, Paul J. Williams, Marie Niewolna, Yakun Wang and Toshiyuki Yoneda Tumor-derived Platelet-derived Growth Factor-BB Plays a Critical Role in Osteosclerotic Bone Metastasis in an Animal Model of Human Breast Cancer [J].Cancer Research2002, 62(1): 917-923.
25. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M.A mouse model of human breast cancer metastasis to human bone [J]. Cancer Res, 2005 ,65(14):6130-6138.
26.Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein[J]. Int J Cancer, 2005, 115(2): 177-186.
27. Neudert M, FiscHer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth[J]. Int J Cancer, 2003, 107(3): 468-477.
28. Waterhouse DN, Gelmon KA, Masin D, Bally MB.Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model[J]. J Exp THer Oncol, 2003, 3(5):261-271.
29. Brodie AH, Jelovac D, Long B.The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens[J]. J Steroid Biochem Mol Biol, 2003, 86(3-5):283-288.
30.Danijela Jelovac, Luciana Macedo, Olga G. Goloubeva, Venkatesh Handratta and Angela M.H. Brodie Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model[J].Cancer Res, 2005, 65(12): 5439-5444.
31. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development [J]. Cancer Res, 2005, 65(18):8166-8173.
32. Lee JL, Chang CJ, Wu SY. Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands[J]. Breast Cancer Res Treat, 2004, 84(2): 139-149.
33. Perez-Alenza MD, Jimenez A, Nieto AI, Pena L. First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases [J]. Breast Cancer Res, 2004, 6(4):R300-307.
34.Raffaella De Maria~1, Martina Olivero, Selina Iussich, Munekazu Nakaichi, Tomoaki Murata, Bartolomeo Biolatti and Maria Flavia Di Renzo. Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer Cancer Research February 1, 2005,65, 907-912,
35. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD.CXCR4 regulates growth of both primary and metastatic breast cancer[J]. Cancer Res, 2004, 64(23):8604-8612.
36.Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, MukHerjee P.Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer[J]. Mol Cancer Res, 2004, 2(11): 632-642.
37.Hu Y,Sun H,Drake J,Kittrell F.From mice to humans:identification of commonly deregulated genes in mammary cancer via comparative SAGE studies [J].Cancer Res,2004,64(21):7748-7755.